GuideAI Health Corp., formerly 1532139 B.C. Ltd., has completed its business combination with GuideAI Health, Inc., creating a public-market platform focused on healthcare artificial intelligence. The transaction was carried out through a plan of arrangement under British Columbia corporate law, with a wholly owned subsidiary acquiring all issued and outstanding securities of GuideAI Health, Inc. The company also changed its name to GuideAI Health Corp., reflecting its renewed focus on clinical intelligence for vascular and cardiovascular care.
Transaction Details
The closing marks a major step in GuideAI Health’s strategy to build and scale AI-powered tools for disease detection, clinical workflow support, and patient management. The company said its platform is designed to convert complex imaging and clinical data into actionable insights for healthcare providers. Its broader aim is to support earlier identification of vascular and cardiovascular conditions while improving care coordination across healthcare systems.
Financing and Listing Plans
Alongside the business combination, GuideAI Health completed a brokered private placement of 5,150,000 subscription receipts at $1.00 each, generating gross proceeds of $5.15 million. The offering was led by Research Capital Corporation and structured so that each subscription receipt will convert into one common share once the required escrow release conditions are met. Following the transaction and financing, the company reported 53,551,525 common shares issued and outstanding.
The company has also filed and received a receipt for its final non-offering prospectus dated June 12, 2026, with securities regulators in British Columbia, Alberta, and Ontario. GuideAI Health has obtained conditional approval to list its common shares on Cboe Canada, though the listing remains subject to customary exchange requirements and final documentation. The prospectus is available through the company’s SEDAR+ profile, with electronic or paper copies also available upon request from the company.
Leadership and Governance
GuideAI Health’s leadership and board were replaced as part of the transaction, positioning the company for its next stage as a healthcare AI business. The management team is now led by Raj Shah as Chief Executive Officer, Paul More as Chief Financial Officer and Corporate Secretary, Tasheel Jeerh as President, and Amin Katouzian as Chief Technology Officer. The board consists of Harry Parmar as Chair, alongside Raj Shah, Paul Sparkes, Elliot Mckerr, and Luke Higgins.
Luke Higgins, Chief Operating Officer and Chief Medical Officer, framed the transaction as a foundation for expanding the company’s clinical and commercial reach. He said the company’s goal is to make advanced vascular and cardiovascular intelligence accessible beyond major academic medical centers. The company believes AI can help healthcare providers detect disease earlier, direct patients to appropriate care more quickly, and improve outcomes across the healthcare system.
Technology Focus
GuideAI Health is developing a clinical intelligence platform aimed at helping healthcare organizations make better use of imaging and patient data. Its solutions are intended to support precision medicine by turning large volumes of clinical information into practical insights that can guide decision-making. This approach could be particularly relevant for hospitals, clinics, and health systems seeking to improve efficiency without relying solely on additional infrastructure or specialist capacity.
The company’s focus on vascular and cardiovascular disease places it in a high-demand area of healthcare, where early diagnosis and coordinated intervention can significantly affect patient outcomes. By applying AI to imaging and clinical data, GuideAI Health is targeting a market where decision support, workflow optimization, and timely detection are becoming increasingly important. The company’s stated mission is to democratize access to advanced clinical intelligence and make precision medicine capabilities available to healthcare systems of different sizes.
GuideAI Health’s completed business combination, financing, and prospectus filing collectively establish the company’s next phase as a healthcare AI issuer pursuing a Cboe Canada listing. The $5.15 million financing provides additional capital as the company works to scale its technology, expand clinical adoption, and build a durable business around AI-enabled care. While the planned listing remains subject to final exchange requirements, the transaction gives GuideAI Health a clearer corporate structure, leadership team, and public-market pathway.